Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng Law Firm confirms that Jiangsu Hualv Biotechnology Group Co., Ltd. has fulfilled the necessary conditions for the second vesting period of its 2023 restricted stock incentive plan and addresses the cancellation of certain unvested restricted stocks [3][4][19]. Group 1: Approval and Authorization - The company has obtained the necessary approvals and authorizations for the implementation of the vesting and cancellation of restricted stocks, including relevant resolutions from the board of directors and supervisory board [7][12][19]. - The independent directors have expressed their agreement with the incentive plan and related resolutions [8][12]. Group 2: Vesting Conditions and Achievements - The second vesting period for the restricted stocks is defined as starting from the first grant date and lasting until the last trading day within 36 months [12][13]. - The vesting conditions include the absence of adverse audit opinions and compliance with performance targets, which have been met as of the date of the legal opinion [13][15]. Group 3: Cancellation of Restricted Stocks - Due to the departure of six incentive targets, a total of 180,000 shares of unvested restricted stocks will be canceled [17][18]. - The cancellation has been approved by the board of directors and does not require further shareholder approval [18][19]. Group 4: Information Disclosure - The company will disclose relevant resolutions and announcements regarding the vesting and cancellation of restricted stocks in accordance with applicable laws and regulations [19].
华绿生物: 上海市锦天城律师事务所关于江苏华绿生物科技集团股份有限公司2023年限制性股票激励计划第二个归属期归属条件成就及部分限制性股票作废相关事项的法律意见书